60 Degrees Pharmaceuticals, Inc. Files Updated Legal Opinion for ATM Equity Offering Program

Washington, D.C., March 12, 2026 – 60 Degrees Pharmaceuticals, Inc. (“the Company” or “60 Degrees Pharma”, Nasdaq: SXTP, SXTPW) has filed a significant update regarding its ongoing “at-the-market” (ATM) equity offering program, which may be of substantial interest to investors and could impact the Company’s share price.

Key Highlights

• Filing of Updated Legal Opinion: On March 12, 2026, the Company filed an updated legal opinion from counsel relating to the shares of common stock issued and sold under its ATM Program. This updated opinion was submitted as Exhibit 5.1 to the Company’s Current Report on Form 8-K.
• ATM Program Details: The ATM equity offering program allows 60 Degrees Pharmaceuticals to issue and sell shares of its common stock, with an aggregate offering price of up to \$981,000, pursuant to a Sales Agreement dated September 5, 2025, between the Company and HC Wainwright & Co., LLC.
• Legal Opinion Scope: The legal opinion confirms that shares issued and sold under this program have been duly authorized and, when issued and sold as described, will be validly issued, fully paid, and non-assessable under applicable law.
• Regulatory Compliance: The legal opinion specifically covers compliance with the laws of the State of New York, the corporation laws of the State of Delaware, and federal securities laws. It provides confirmation regarding the validity of the shares and certain matters related to the offering under these jurisdictions.
• No Change to ATM Terms: The Company emphasized that the filing and the updated legal opinion do not affect the terms of the ATM Program. The purpose is to confirm the legal standing of the shares to be issued, as required for continued regulatory compliance.
• Emerging Growth Company Status: 60 Degrees Pharmaceuticals continues to identify as an “emerging growth company” under Rule 405 of the Securities Act of 1933, which may allow for certain reduced reporting requirements and transition periods for new or revised accounting standards.
• Exchange Listings: The Company’s common stock and warrants are listed on the Nasdaq Stock Market LLC under the symbols SXTP and SXTPW.

Details and Potential Price Sensitivity

• Potential Dilution: The ATM program gives the Company flexibility to raise capital by selling common stock into the market at prevailing prices. The issuance of new shares, if and when executed, could lead to dilution for existing shareholders. Investors should monitor future filings to track amounts actually raised and shares issued under the program.
• Regulatory and Legal Transparency: By updating and publicly filing the legal opinion, the Company is proactively ensuring ongoing compliance with SEC requirements. This transparency may bolster investor confidence in the Company’s governance and legal standing.
• Liquidity and Funding: The ATM facility, with a remaining capacity of up to \$981,000, provides the Company with a flexible funding mechanism. This could support operational needs, research and development, or other strategic initiatives, potentially enhancing the Company’s financial position.

What Shareholders Should Know

• This filing does not represent a new financing round or immediate issuance of shares, but confirms the validity and authorization for shares issued in the future under the existing ATM program.
• There is no change to the Company’s business operations announced in this report. The update is legal and procedural in nature, supporting the Company’s ability to utilize the ATM program as needed.
• The Company’s status as an emerging growth company may allow it to take advantage of certain regulatory accommodations, which could have implications for disclosure, governance, and transition periods for accounting changes.

Signatories

The report was signed by Geoffrey Dow, Chief Executive Officer and President of 60 Degrees Pharmaceuticals, Inc., confirming the Company’s commitment to regulatory compliance and transparency.

Conclusion

This filing is mainly procedural but important for legal and regulatory compliance. While it does not alter the terms of the ATM program or signal new business developments, it reinforces the Company’s ability to raise capital via equity markets as opportunities or needs arise. Investors should continue to monitor the Company for announcements regarding the actual use of the ATM facility, as such actions may have a direct impact on share count, dilution, and capital resources.

Disclaimer: This article is prepared for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should perform their own due diligence and consult with their financial advisors before making investment decisions. The information contained herein is based on publicly available filings as of March 12, 2026, and may be subject to change.

View 60 DEGREES PHARMACEUTICALS, INC. Historical chart here